Ketotifen is a second-generation, orally active, non-competitive histamine 1 (H1) receptor blocker and mast cell stabilizer that inhibits 6-phosphogluconate dehydrogenase (6-PGD) in vitro. Ketotifen exhibits antiviral activity against SARS-CoV-2 and influenza virus and is suitable for research on experimental autoimmune encephalomyelitis (EAE) and asthma attack prevention.
